Cargando…

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

BACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minchom, Anna, Yuan, Wei, Crespo, Mateus, Gurel, Bora, Figueiredo, Ines, Wotherspoon, Andrew, Miranda, Susana, Riisnaes, Ruth, Ferreira, Ana, Bertan, Claudia, Pereira, Rita, Clarke, Matt, Baker, Chloe, Ang, Joo Ern, Fotiadis, Nicos, Tunariu, Nina, Carreira, Suzanne, Popat, Sanjay, O'Brien, Mary, Banerji, Udai, de Bono, Johann, Lopez, Juanita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069263/ https://www.ncbi.nlm.nih.gov/pubmed/32169873 http://dx.doi.org/10.1136/jitc-2020-000713

Ejemplares similares

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2020)

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2021)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
por: Tiu, Crescens, et al.
Publicado: (2020)

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
por: Tiu, Crescens, et al.
Publicado: (2021)

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
por: Banerjee, Susana, et al.
Publicado: (2022)

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
por: Zafeiriou, Zafeiris, et al.
Publicado: (2019)

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
por: Coker, Elizabeth A., et al.
Publicado: (2022)

Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations
por: Curcean, Sebastian, et al.
Publicado: (2021)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
por: Ikeda, Taro, et al.
Publicado: (2021)

Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
por: Grosso, Federica, et al.
Publicado: (2018)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
por: Minchom, Anna, et al.
Publicado: (2017)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023)

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
por: Paschalis, Alec, et al.
Publicado: (2019)

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
por: Ang, Joo Ern, et al.
Publicado: (2012)

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
por: Pal, Abhijit, et al.
Publicado: (2021)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020)

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
por: Ingles Garces, Alvaro H., et al.
Publicado: (2018)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
por: Carausu, Marcela, et al.
Publicado: (2019)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing
por: Donners, Ricardo, et al.
Publicado: (2022)

Malignant Deciduoid Mesothelioma: case presentation of an exceptional variant and review of the literature
por: Khmou, Mouna, et al.
Publicado: (2017)

Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
por: Bickel, Angelika, et al.
Publicado: (2016)

Pembrolizumab-Associated CD8(+) Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
por: Baldauf, Michaela C., et al.
Publicado: (2021)

Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
por: Dolly, Saoirse O, et al.
Publicado: (2017)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
por: Carreira, Suzanne, et al.
Publicado: (2021)

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
por: Ahmadzada, Tamkin, et al.
Publicado: (2020)

Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab
por: Mampuya, Wambaka Ange, et al.
Publicado: (2021)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Lithium rechallenge after renal transplant
por: Beasley, Anna K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dhtigihi78d931kvr35j6kapee